Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Kane JM, Correll CU
European Heart Journal - Cardiovascular Pharmacotherapy 10(4):296306 Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A et al (2021) GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes
Bredella, M
Tirzepatide activates both GLP-1 and GIP receptors, delivering average weight loss of 2022% in clinical studiesroughly 57 percentage points greater than semaglutide
These mechanisms operate through distinct biological pathways, meaning they theoretically complement rather than compete
US$ 27.95
US$ 22.83
US$ 24.23
US$ 23.58
